Excluding signaling pathways unrelated to the disease, the results of KEGG enrichment analysis showed that the drug treated RA by acting on PI3K-AKT, JAK-STAT, HIF-1, and other signaling pathways. This evidence concerns the gene PIK3CA and rheumatoid arthritis.